CBAY News and Press, CymaBay Therapeutics Inc. From 07/20/23

2023-07-20 06:50:16 ET Summary CymaBay Therapeutics' primary candidate, seladelpar, shows promising results as a potential treatment for primary biliary cholangitis, a liver autoimmune disease. Seladelpar demonstrated significant anti-cholestatic, anti-inflammatory, and anti-pruri...

2023-07-13 08:04:34 ET Intercept Pharmaceuticals ( NASDAQ: ICPT ) gained ~10% pre-market Thursday after H.C. Wainwright upgraded it to Buy from Sell, citing a novel drug combination the company is developing for an autoimmune disease called primary biliary cholangitis (PBC). ...

CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is one of today's top gainers. The company's shares are currently up 41.96% on the day to $11.13. CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic dis...

2023-06-30 11:50:47 ET Shares of CymaBay Therapeutics (NASDAQ: CBAY) were up more than 37% as of 11:15 a.m. ET on Friday. The clinical-stage biotech saw its shares rise after Ipsen and Genfit announced phase 3 trials data for elafibranor to treat the rare autoimmune live...

2023-06-30 10:06:37 ET Gainers: CymaBay Therapeutics ( CBAY ) +36% . Cyteir Therapeutics ( CYT ) +34% . Renalytix ( RNLX ) +32% . CytomX Therapeutics ( CTMX ) +14% . Alvotech ( ALVO ) +13% . Losers: Unicycive Therapeutics ...

2023-06-30 08:40:05 ET Renalytix ( RNLX ) +38% jumps 38% after FDA nod for lead product. TOP Financial Group  ( TOP ) +25% . Bright Health Group ( BHG ) +19% enters into definitive agreement with Molina Healthcare to sell its California Medicare Adva...

CymaBay Therapeutics Presents Data Showing Seladelpar Treatment in Primary Biliary Cholangitis (PBC) Correlates with Alleviation of Self-Reported Pruritus and Reduction in Serum IL-31 Levels PR Newswire Additional data presented at The International Liver Congress™ 2023...

CymaBay Therapeutics to Present New Data Highlighting Seladelpar's Unique Activity in Patients with Primary Biliary Cholangitis at The International Liver Congress™ 2023 PR Newswire Two abstracts focus on the unique mechanism of action of seladelpar; a third focuses o...

2023-05-19 17:59:16 ET A significant miss on quarterly earnings combined with a big change in its C-suite put a damper on CymaBay Therapeutics (NASDAQ: CBAY) stock this week. According to data compiled by S&P Global Market Intelligence , the biotech's stock suffered an 11% d...

2023-05-15 22:52:02 ET CymaBay Therapeutics, Inc. (CBAY) Q1 2023 Earnings Conference Call May 15, 2023, 16:30 PM ET Company Participants Paul Quinlan - General Counsel Sujal Shah - President and Chief Executive Officer Charles McWherter - Chief Scientific Officer...